ACRV

Acrivon Therapeutics, Inc.

• TipRanks·03/23 08:25

  Jefferies Keeps Their Buy Rating on Acrivon Therapeutics, Inc. (ACRV)

• TipRanks·03/20 10:20

  Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Scholar Rock Holding (SRRK) and Acrivon Therapeutics, Inc. (ACRV)

• TipRanks·03/19 11:49

  Acrivon Highlights Positive ACR-368 Data and 2025 Results

• TipRanks·03/19 11:31

  Acrivon plans to initiate fourth cohort in ACR-368 Phase 2b study

• Reuters·03/19 11:28

  Acrivon Therapeutics Q4 net loss narrows as expenses fall

• TipRanks·03/19 11:25

  Acrivon Therapeutics sees cash runway into 2Q27

• Benzinga·03/19 11:23

  Acrivon Therapeutics Q4 EPS $(0.49) Beats $(0.57) Estimate

• Reuters·03/19 11:22

  BRIEF-Acrivon Therapeutics, Inc Q4 Income From Operations USD -20.116 Million

• Dow Jones·03/19 11:22

  *Acrivon Therapeutics 4Q Loss/Shr 49c >ACRV

• Dow Jones·03/19 11:22

  *Acrivon Therapeutics 4Q Research and Development Expenses $14.7M >ACRV

• Reuters·03/19 11:21

  ACRIVON THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

• Reuters·03/19 11:12

  Acrivon FY 2025 net loss narrows 5.4% to USD 77.9 million as interest income falls 29.6% to USD 6.48 million

• Benzinga·03/17 21:57

  Acrivon Therapeutics To Reveal Pre-Clinical AP3 Data At The 2026 AACR Annual Meeting

• Reuters·03/17 21:54

  Acrivon Therapeutics to present three posters at the AACR Annual Meeting

• TipRanks·03/02 12:46

  Piper Sandler Remains a Buy on Acrivon Therapeutics, Inc. (ACRV)